123P 在 PD-1/PD-L1 抗药性黑色素瘤或 NSCLC 患者中开展的一项 nivolumab (N) 加 ipilimumab (I) 和 ASTX727 或 N 加 I 的 II 期研究：NIBIT基金会ML1研究的试验阶段

{"title":"123P 在 PD-1/PD-L1 抗药性黑色素瘤或 NSCLC 患者中开展的一项 nivolumab (N) 加 ipilimumab (I) 和 ASTX727 或 N 加 I 的 II 期研究：NIBIT基金会ML1研究的试验阶段","authors":"A. M. Di Giacomo, G. Rossi, L. Calabro, A. Pascucci, V. Vegni, E. Simonetti, M. Colucci, M. Valente, G. Gibilisco, F. Frongia, M.F. Lofiego, G. Amato, H.N. Keer, A. Oganesian, D. Chan, D. Giannarelli, M. Ceccarelli, A. Anichini, A. Covre, M. Maio","doi":"10.1016/j.iotech.2023.100595","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 69","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study\",\"authors\":\"A. M. Di Giacomo, G. Rossi, L. Calabro, A. Pascucci, V. Vegni, E. Simonetti, M. Colucci, M. Valente, G. Gibilisco, F. Frongia, M.F. Lofiego, G. Amato, H.N. Keer, A. Oganesian, D. Chan, D. Giannarelli, M. Ceccarelli, A. Anichini, A. Covre, M. Maio\",\"doi\":\"10.1016/j.iotech.2023.100595\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":192507,\"journal\":{\"name\":\"Immuno-Oncology and Technology\",\"volume\":\" 69\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-Oncology and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.iotech.2023.100595\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100595","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}